Abstract 1851P
Background
We have previously reported on the initial results of the prospective longitudinal PICO-SM study (Lim et al. 2023), highlighting the impact of the COVID-19 pandemic on the lives of patients with colorectal cancer. Herein, we present the psychological impact of the third wave of the pandemic to patients, when the Omicron variant became prevalent (December 2021 to early 2022).
Methods
Patients were invited to participate in cohort II of the PICO-SM study by completing a questionnaire, including screening psychometric tools. Multivariate analysis was performed using logistic regression for binary outcomes: anxiety (GAD-7 score ≥ 5), depression (PHQ-9 score ≥ 10), and poor well-being (WHO-5 < 50); and odds ratios (OR) with 95% confidence interval (CI) were calculated.
Results
In total, 96 participants were included: mean age 64 years, 64% (n = 61) males. 33% (n = 32/96) reported poor well-being (WHO-5 < 50), 27% (n = 26/96) anxiety (GAD-7 ≥ 5), 11% (n = 11/96) depressive symptoms (PHQ-9 ≥ 10) and 3% (n = 3/96) probable post-traumatic stress disorder (PC-PTSD-5 ≥ 4). The results compare with distress levels in the second pandemic wave: 31%, 24%, 15% and 3%, respectively. Multivariate analysis showed that patients who had investigations cancelled (OR 9.22, 95% CI 1.09-77.85; p = 0.041) or felt that the pandemic would affect their mental health (OR 3.82, 95% CI 1.96-7.44; p < 0.001) had increased risk of anxiety. Similarly, concern that the pandemic would affect their cancer treatment (OR 4.59, 95% CI 1.03-20.56; p = 0.046) or would affect their mental health (OR 3.90, 95% CI 1.38-11.03; p = 0.010) were found independent predictors of poor wellbeing.
Conclusions
The psychological distress experienced by patients, particularly anxiety, remained persistently high during the third wave of the COVID-19 pandemic. These updated results align with our initial findings, emphasizing the critical importance of continuing cancer treatment amidst the ongoing humanitarian emergency. It is crucial for healthcare services to prioritize ongoing psychological support for cancer patients, with a particular focus on those who are more vulnerable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Servier.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05